Last reviewed · How we verify
Alphagan
At a glance
| Generic name | Alphagan |
|---|---|
| Also known as | Brimonidine |
| Sponsor | Bp Consulting, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Brimonidine 0.33% for Rosacea-Related Facial Erythema (PHASE4)
- High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia (NA)
- Upneeq vs. Lumify Ptosis (PHASE4)
- The PASTDUe Nutrition Ecosystem Project (PASTDUe) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |